Draft:Strategic Clinical Innovation Organization
| Submission declined on 9 April 2025 by Ca (talk). Neologisms are not considered suitable for Wikipedia unless they receive substantial use and press coverage; this requires strong evidence in independent, reliable, published sources. Links to sites specifically intended to promote the neologism itself do not establish its notability.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: The cited journals seem to be predatory and unreliable, and are written by authors affilated with Boston Biotech Clinical Research. Please remove unreliable sources and follow the guideline WP:MEDRS. Ca talk to me! 07:49, 9 April 2025 (UTC)
Strategic Clinical Innovation Organization (SCIO) is an early development procedure that overcomes silos and eliminates the "one at a time" method.[1][2][3] It uses computational methods to investigate epigenetics, genetics, and bioinformatics.[4] It was developed by Boston Biotech Clinical Research (BBCR).[3][5]
History
[edit]Boston Biotech Clinical Research was founded by Candida Fratazzi.[6][7] To reduce costs and speed up development, the company works with biotech, pharmaceutical, and medical device companies to create clinical protocols, programs, and efficient trials.[4]
Concept
[edit]The SCIO concept is predicated on three pillars: clinical investigation, trial design and analysis of data gathered during phases I and II, and compliance with regulatory mandates and the use of surrogate biomarkers. The aim of the SCIO method is to stratify the patient population in order to increase the proportion of patients who respond favorably to a given medication, raising it from about 20 percent to 80 percent.[4]
Using the SCIO method, non-clinical molecular proteomics can be integrated into clinical research. This improves the regulatory strategy of accumulating efficacy and safety evidence from the first human trials onwards, which in turn reduces the risk of late-stage clinical trials and better positions the product for the market.[4]
References
[edit]- ^ https://zealjournals.com/wjapmr/sites/default/files/WJAPMR-2022-0021.pdf
- ^ Candida Fratazzi; Jixiao Niu (January 21, 2022). "Accelerated orphan drug approval: surrogate endpoints". World Journal of Advanced Pharmaceutical and Medical Research. 2: 001–007. doi:10.53346/wjapmr.2022.2.1.0021. S2CID 246338312.
- ^ a b Bs, Wade Fox (September 26, 2023). "Precision medicine for all common diseases with the SCIOSM method". GSC Biological and Pharmaceutical Sciences. 24 (3): 149–153. doi:10.30574/gscbps.2023.24.3.0255. S2CID 262029797 – via gsconlinepress.com.
- ^ a b c d "BBCR". Life Sciences Review. Retrieved 2024-02-01.
- ^ Fratazzi, Candida (2015-10-26). "Cost-effective clinical trial design to detect immunogenicity and efficacy differences between biosimilar and innovator product". Journal of Bioanalysis & Biomedicine. ISSN 1948-593X.
- ^ https://www.hilarispublisher.com/conference-abstracts-files/1948-593X-C3-043-004.pdf
- ^ "Challenges Exist in Implementing Biosimilars for Rheumatoid Conditions". Pharmacy Times. November 28, 2016.